FIGURE 1.

Bcl1 cells differentiate with IL-5 and LPS treatment. A, Bcl1 cells were treated with IL-5 and LPS for 72 h prior to collection and staining. B cell and plasma cell markers were measured by flow cytometry. B–D, Bcl1 cells were untreated (NT) or pretreated with tunicamycin (Tm) for 5 h prior to treatment with IL-5 and/or LPS for 96 h. B, apoptosis was measured by annexin V and propidium iodide staining. C, IgM was measured by ELISA of the supernatant of the various treatment groups and is reported as a function of the live cell number. D, IgM was measured by ELISA of the lysates of the various treatment groups and is reported as a function of the live cell number contributing to the lysate. Data are represented as the mean ± S.E. of three independent experiments (*, p < 0.05, **, p < 0.01).